Review of the Development of General Chapters in the 2020 Edition of the Chinese Pharmacopoeia

In July 2020, the National Medical Products Administration and the National Health Commission of China approved the 2020 edition of the Chinese Pharmacopoeia, which was officially enacted on December 30, 2020. The general chapters serve as the foundation for drug standards, detailing common testing procedures and implementation guidelines. Compared to previous editions, the 2020 version demonstrates notable enhancements, emphasizing scientific validity, broad applicability, practical operability, and sustainable development. This edition expands the use of sophisticated analytical technologies, strengthens methods for detecting external contaminants in traditional Chinese medicines, and aligns technical criteria more closely with global standards. By providing updated methodological and technical guidance, it supports the safe and effective regulation of pharmaceuticals in China, promotes adoption of advanced technologies, improves quality control, and reinforces regulatory measures. This review offers a thorough summary of the main updates and characteristics of the general chapters in the 2020 edition, aiming to facilitate accurate understanding and proper application.